Company intelligence / Profile preview

Kian Immune Cell Company

Tehran, Tehran Province, Irankiacell-immune.com ↗

Ownership: Private
Employees: ~10
Development stage: Preclinical

Overview

NiKogene has reached Phase II clinical development targeting relapsed/refractory pediatric DIPG. The company has completed two Phase I studies with its allogenic NK cell product bank focused on brain tumors. Its products are not yet exported but have the potential to serve a significant portion of domestic cancer patients upon regulatory approval.

Therapeutic areas: Oncology
Modalities: Allogeneic Natural Killer (NK) cellsGenetically modified immune cellsHematopoietic stem cells3D cell culture models/spheroidsChemobiogram kit for drug sensitivity testing
Industry: Biotech

Drug pipeline

4 assets

Niktoraal

Preclinical

3 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Kian Immune Cell Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Kian Immune Cell Company.

Explore the full profile